Roivant executive exercises options, sells 200K shares

Rhea-AI Filing Summary

Roivant Sciences Ltd. President & Immunovant CEO Eric Venker exercised stock options for 200,000 Common Shares at an exercise price of $3.85 per share and on the same day sold 200,000 Common Shares in open-market transactions at a weighted average price of $28.24 per share.

Following these transactions, Venker directly owned 1,647,546 Common Shares. The sale price reflects multiple trades within a range from $28.04 to $28.45, as disclosed in the filing footnotes.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 3 txns

Insider Venker Eric

Role President & Immunovant CEO

Sold 200,000 shs ($5.65M)

Approx. gross sale proceeds $5.65M

Approx. exercise cost $770K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	200,000	$0.00	$0.00
Exercise	Common Shares	200,000	$3.85	$770K
Sale	Common Shares	200,000	$28.24	$5.65M

Holdings After Transaction: Stock Option (Right to Buy) — 4,844,834 contracts (Direct); Common Shares — 1,647,546 shares (Direct)

Footnotes (2)

1. F1. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.04 to $28.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
2. F2. Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Roivant Sciences (ROIV) executive Eric Venker report in this Form 4?

Eric Venker reported exercising options for 200,000 Roivant Sciences Common Shares and selling 200,000 shares the same day. These transactions converted an option position into shares, then into cash through open-market sales at a weighted average price of $28.24.

How many Roivant Sciences (ROIV) shares did Eric Venker sell and at what price?

Eric Venker sold 200,000 Roivant Sciences Common Shares in open-market transactions at a weighted average price of $28.24 per share. Footnotes state individual trades occurred between $28.04 and $28.45, and detailed trade breakdowns are available on request.

What stock option exercise did Eric Venker report for Roivant Sciences (ROIV)?

Eric Venker exercised stock options covering 200,000 Roivant Sciences Common Shares at an exercise price of $3.85 per share. These options were part of an award that began vesting on April 20, 2022, with vesting over several years subject to continued service.

How many Roivant Sciences (ROIV) shares does Eric Venker own after these transactions?

After exercising options and selling shares, Eric Venker directly owned 1,647,546 Roivant Sciences Common Shares. This figure reflects his remaining direct equity stake following the 200,000-share open-market sale disclosed in the Form 4 filing for the reported date.

Were Eric Venker’s Roivant Sciences (ROIV) share sales made in multiple trades?

Yes. The filing notes that Eric Venker’s 200,000 Roivant Sciences shares were sold in multiple transactions. The weighted average sale price was $28.24, with individual trade prices ranging from $28.04 to $28.45, all occurring on the same reported date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/19/2026 - 06:36 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Venker Eric

(Last) (First) (Middle)

C/O ROIVANT SCIENCES LTD.

7TH FLOOR, 50 BROADWAY

(Street)

LONDON SW1H 0DB

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
Roivant Sciences Ltd. [ ROIV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & Immunovant CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	03/17/2026		M		200,000	A	$3.85	1,847,546	D
Common Shares	03/17/2026		S		200,000	D	$28.24(1)	1,647,546	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.85	03/17/2026		M			200,000	(2)	04/19/2032	Common Stock	200,000	$0	4,844,834	D

Explanation of Responses:

1. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.04 to $28.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

2. Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).

Remarks:

	By: /s/ Jo Chen, as Attorney-in-Fact for Eric Venker	03/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)